Table 4.
Absorbed dose recommendations for 166Ho microspheres and the respective level of evidence (LOE)
| One-compartment | Multi-compartment | ||||
|---|---|---|---|---|---|
| Clinical scenario | Perfused volume dose | LOE | Whole normal liver dose | Tumour dose | LOE |
| HCC | |||||
| Segmentectomy | 60 | 3 | Not applicable | ||
| Lobectomy | 60 | 3 | < 60 | Not available | 4 |
| Unilobar | 60 | 3 | < 60 | Not available | 4 |
| Bilobar | 60 | 3 | < 40*** | Not available | 4 |
| ICC | |||||
| Segmentectomy | 60 | 3 | Not applicable | ||
| Lobectomy | 60 | 3 | < 60 | > 150* | 3–4 |
| Unilobar | 60 | 3 | < 60 | > 150* | 3–4 |
| Bilobar | 60 | 3 | < 40*** [96] | > 150* [96] | 3–4 |
| mCRC | |||||
| Segmentectomy | 60 | 3 | Not applicable | ||
| Lobectomy | 60 | 3 | < 60 | > 90** [97] | 3 |
| Unilobar | 60 | 3 | < 60 | > 90** [97] | 3 |
| Bilobar | 60 | 3 | < 40*** | > 90** [97] | 3 |
LOE, level of evidence
*Based on median tumour absorbed dose for stable disease in a mixed population
**Based on 100% sensitivity for response
***Up to 60 Gy in patients with more favourable liver function